AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
AAPL   322.32 (-0.86%)
MSFT   182.92 (-1.32%)
FB   226.29 (-1.68%)
GOOGL   1,414.30 (-1.73%)
AMZN   2,460.60 (-0.72%)
NVDA   350.66 (-0.03%)
CGC   16.63 (+0.36%)
BABA   218.04 (-0.26%)
MU   51.22 (+4.70%)
GE   7.74 (+5.16%)
TSLA   864.38 (-2.10%)
AMD   52.63 (-0.19%)
T   31.80 (+0.92%)
ACB   14.23 (-0.49%)
F   6.57 (+6.14%)
GILD   77.54 (+4.22%)
DIS   123.69 (+1.24%)
NFLX   414.33 (-1.81%)
BAC   26.78 (+3.04%)
BA   184.30 (+6.43%)
Log in

NASDAQ:NTRANatera Stock Price, Forecast & News

$43.35
-1.66 (-3.69 %)
(As of 06/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$43.28
Now: $43.35
$45.13
50-Day Range
$31.19
MA: $40.60
$46.95
52-Week Range
$16.87
Now: $43.35
$49.22
Volume622,200 shs
Average Volume968,776 shs
Market Capitalization$3.41 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.37
Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Evercord, a cord blood and cord tissue processing and storage service; and Signatera, a circulating tumor DNA technology that analyzes and tracks mutations to an individual's tumor. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners in the United States and internationally. Natera, Inc. has research collaborations with the Institut Jules Bordet and Fox Chase Cancer Center. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Read More
Natera logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTRA
CUSIPN/A
Phone650-249-9090

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$302.33 million
Book Value$3.59 per share

Profitability

Net Income$-124,830,000.00

Miscellaneous

Employees1,039
Market Cap$3.41 billion
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive NTRA News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter.

Natera (NASDAQ:NTRA) Frequently Asked Questions

How has Natera's stock been impacted by COVID-19 (Coronavirus)?

Natera's stock was trading at $31.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NTRA shares have increased by 39.7% and is now trading at $43.35. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Natera?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Natera.

When is Natera's next earnings date?

Natera is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Natera.

How were Natera's earnings last quarter?

Natera Inc (NASDAQ:NTRA) announced its quarterly earnings results on Wednesday, May, 6th. The medical research company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.12. The medical research company had revenue of $94.01 million for the quarter, compared to the consensus estimate of $85.02 million. Natera had a negative return on equity of 78.56% and a negative net margin of 38.28%. Natera's revenue was up 40.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.54) EPS. View Natera's earnings history.

What guidance has Natera issued on next quarter's earnings?

Natera updated its first quarter 2020 Pre-Market earnings guidance on Monday, April, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $89-91 million, compared to the consensus revenue estimate of $79.45 million.

What price target have analysts set for NTRA?

8 brokerages have issued 12-month price objectives for Natera's stock. Their forecasts range from $36.00 to $56.00. On average, they anticipate Natera's share price to reach $45.13 in the next year. This suggests a possible upside of 4.1% from the stock's current price. View analysts' price targets for Natera.

What are Wall Street analysts saying about Natera stock?

Here are some recent quotes from research analysts about Natera stock:
  • 1. According to Zacks Investment Research, "Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. " (5/12/2020)
  • 2. Canaccord Genuity analysts commented, "We recently had the privilege of hosting Natera CEO Steve Chapman and CFO a well-attended fireside chat at the 39th in Boston. We continue to view NTRA as an undervalued cancer company trading at the multiple of an NIPT company. NTRA remains one of our favorite stocks and is one of our top picks for 2019. We reiterate our BUY rating and $38 PT. Signatera may be a game-changer in recurrence monitoring and MRD." (9/11/2019)

Has Natera been receiving favorable news coverage?

News coverage about NTRA stock has been trending very negative on Thursday, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Natera earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news aboutNatera.

Who are some of Natera's key competitors?

What other stocks do shareholders of Natera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Athabasca Oil (ATH), Chipotle Mexican Grill (CMG), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

Who are Natera's key executives?

Natera's management team includes the following people:
  • Dr. Matthew Rabinowitz, Co-Founder & Exec. Chairman (Age 46)
  • Mr. Steve Chapman, CEO, Pres & Director (Age 40)
  • Mr. Michael Brophy, Chief Financial Officer (Age 39)
  • Mr. Jonathan Sheena, Co-Founder, Chief Technology Officer & Director (Age 46)
  • Mr. Robert A. Schueren, Chief Operating Officer (Age 57)

When did Natera IPO?

(NTRA) raised $101 million in an IPO on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

What is Natera's stock symbol?

Natera trades on the NASDAQ under the ticker symbol "NTRA."

Who are Natera's major shareholders?

Natera's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.10%), Orbimed Advisors LLC (4.25%), Fred Alger Management LLC (4.19%), Wells Fargo & Company MN (3.74%), JPMorgan Chase & Co. (3.66%) and State Street Corp (3.23%). Company insiders that own Natera stock include Gail Boxer Marcus, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren and Steven Leonard Chapman. View institutional ownership trends for Natera.

Which institutional investors are selling Natera stock?

NTRA stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Invesco Ltd., Fred Alger Management LLC, Federated Hermes Inc., Morgan Stanley, Morgan Stanley, Nuveen Asset Management LLC, and Jennison Associates LLC. Company insiders that have sold Natera company stock in the last year include Gail Boxer Marcus, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren, and Steven Leonard Chapman. View insider buying and selling activity for Natera.

Which institutional investors are buying Natera stock?

NTRA stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Orbimed Advisors LLC, Wells Fargo & Company MN, Loomis Sayles & Co. L P, Driehaus Capital Management LLC, Two Sigma Advisers LP, Castleark Management LLC, and Balyasny Asset Management LLC. View insider buying and selling activity for Natera.

How do I buy shares of Natera?

Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Natera's stock price today?

One share of NTRA stock can currently be purchased for approximately $43.35.

How big of a company is Natera?

Natera has a market capitalization of $3.41 billion and generates $302.33 million in revenue each year. The medical research company earns $-124,830,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Natera employs 1,039 workers across the globe.

What is Natera's official website?

The official website for Natera is www.natera.com.

How can I contact Natera?

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.